Patients treated with the basal-bolus insulin regimen attained lower fasting blood glucose (10.8±2.3 versus 11.6±3.5 mmol/L; p = 0.028) and mean glucose levels (12.3±1.9 versus 12.8±2.2; p = 0.021) throughout severe or acute hyperglycemia compared with sliding-scale insulin regimens. The gene discussed is INS; the disease is Hyperglycemia.